MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

GTx Company Profile (NASDAQ:GTXI)

Consensus Ratings for GTx (NASDAQ:GTXI) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for GTx (NASDAQ:GTXI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for GTx (NASDAQ:GTXI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/10/2016Q1($0.04)$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.10)($0.04)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q315($0.06)($0.04)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.04)($0.34)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q1($0.04)($0.04)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015Q314($0.07)($0.05)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q214($0.11)($0.06)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q2($0.12)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.12)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2014Q413($0.13)($0.12)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q313($0.21)($0.14)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/19/2013Q2 2013($0.22)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2013Q1 2013($0.21)($0.20)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/21/2013Q4 2012($0.21)($0.17)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.17)$0.12$1.93 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2012($0.17)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012($0.17)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/21/2012($0.17)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2011($0.18)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2011($0.19)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2011($0.13)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2011($0.16)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for GTx (NASDAQ:GTXI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.04)($0.04)($0.04)
Q2 20161($0.05)($0.05)($0.05)
Q3 20161($0.03)($0.03)($0.03)
Q4 20161($0.03)($0.03)($0.03)
(Data provided by Zacks Investment Research)
Dividend History for GTx (NASDAQ:GTXI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for GTx (NASDAQ:GTXI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/16/2016Robert James WillsChairmanBuy100,000$0.65$65,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016J Kenneth GlassDirectorBuy44,000$0.60$26,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2016Marc Steven HanoverCEOBuy4,000$0.65$2,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/25/2016Marc Steven HanoverCEOBuy12,813$0.63$8,072.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Marc Steven HanoverCEOBuy25,000$0.50$12,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2016Marc Steven HanoverCEOBuy25,000$0.49$12,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2015J Kenneth GlassDirectorBuy100$0.79$79.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2015J Kenneth GlassDirectorBuy1,907$0.78$1,487.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015J Kenneth GlassDirectorBuy39,900$0.78$31,122.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2015J Kenneth GlassDirectorBuy24,500$1.25$30,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2015Robert James WillsChairmanBuy46,140$0.96$44,294.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2015Henry Patton DoggrellVPBuy25,477$0.80$20,381.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2015Robert James WillsChairmanBuy50,000$0.80$40,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2015J Kenneth GlassDirectorBuy10,000$0.72$7,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/21/2015J Kenneth GlassDirectorBuy11,608$0.71$8,241.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015J Kenneth GlassDirectorBuy3,300$0.72$2,376.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015J Kenneth GlassDirectorBuy16,400$0.67$10,988.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2014Marc Steven HanoverCEOBuy5,000$0.75$3,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Marc Steven HanoverCEOBuy10,000$0.74$7,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2014Marc Steven HanoverCEOBuy20,000$1.00$20,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014Marc Steven HanoverCEOBuy10,000$1.01$10,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/8/2014Henry Patton DoggrellVPBuy10,000$0.97$9,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/8/2014Marc Steven HanoverCEOBuy30,000$0.93$27,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Jason T ShackelfordInsiderBuy10,000$0.92$9,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Marc Steven HanoverCEOBuy30,000$0.92$27,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2014James T DaltonVPSell72,883$1.30$94,747.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Jack Schulermajor shareholderSell1,192,251$1.84$2,193,741.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2013Jack Schulermajor shareholderBuy93,777$1.36$127,536.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2013Jack Schulermajor shareholderBuy309,591$1.42$439,619.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2013Mark Edward MostellerCFOSell17,000$6.99$118,830.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2013James T DaltonVPSell20,000$5.20$104,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2012Timothy R G SearDirectorBuy50,000$4.33$216,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2012J Kenneth GlassDirectorBuy10,000$3.76$37,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for GTx (NASDAQ:GTXI)
DateHeadline
06/22/16 04:27 PMGTX INC /DE/ : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
06/22/16 09:01 AMGTX INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tran -
06/22/16 08:59 AMGTx, Inc Therapeutics Drugs and Companies Pipeline Review H1 2016 Research Report
06/21/16 07:15 AMGTx (GTXI) Shows Strength: Stock Adds 11.2% in Session -
06/20/16 10:34 AMForm 4 GTX INC /DE/ For: Jun 16 Filed by: Wills Robert James
06/17/16 01:29 AMGIGABYTE Releases GeForce® GTX 1070 G1 GAMING Graphics Card - [at noodls] - GV-N1070G1 GAMING-8GD Taipei, Taiwan, June 16, 2016 - GIGABYTE, the world's leading premium gaming hardware manufacturer, today released the GeForce® GTX 1070 G1 GAMING graphics card (GV-N1070G1 GAMING-8GD). ...
06/08/16 05:07 PMGTx, Inc. :GTXI-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/07/16 09:28 AMGIGABYTE Launches GeForce® GTX 1080 XTREME GAMING Graphics Card - [at noodls] - Unprecedented performance integrated with GIGABYTE innovation ready for next-generation gaming GV-N1080XTREME-8GD Premium Pack Taipei, Taiwan, June 6, 2016 - GIGABYTE, the world's leading premium gaming ...
06/02/16 10:30 PMGTx, Inc. Pipeline Review, Industry Analysis, Market Size and Forecast 2016 to 2020 - “GTx, Inc. Global 2015 Clinical Trials Review, H2” provides an detailed overview of GTx, Inc. scenario. Report includes top line data relating on GTx, Inc. Global clinical trials scenario. This report on GTx, Inc. also includes an review of trial ...
06/02/16 06:15 AMGTx Announces Webcast of Corporate Presentation at Jefferies 2016 Global Healthcare Conference - [at noodls] - MEMPHIS, Tenn.--(BUSINESS WIRE)--Jun. 2, 2016-- GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on June 9, 2016, at the Jefferies 2016 Global Healthcare Conference ...
05/31/16 09:52 AMCritics Call GeForce GTX 1070 “One Hell of a Graphics Card,” “Major Value,” “Significant Leap” - [at noodls] - Reviewers are describing our new GeForce GTX 1070 GPU as as an ideal mix of price, performance, and power consumption, in a series of technical reviews that began rolling in over the weekend. Introduced ...
05/29/16 01:20 PMGtx Incorporated (NASDAQ:GTXI) Sellers Covered 15.99% of Their Shorts - HNN - Gtx Incorporated (NASDAQ:GTXI) Sellers Covered 15.99% of Their ShortsHNNThe short interest to Gtx Incorporated's float is 1.41%. The stock decreased 4.00% or $0.03 on May 27, hitting $0.72. About 15,261 shares traded hands. GTx, Inc. (NASDAQ:GTXI) has declined 31.43% since October 22, 2015 and is downtrending.and more »
05/27/16 01:53 PMToday's Watch List: Curis, Inc. (NASDAQ:CRIS), Innocoll Holdings plc (NASDAQ:INNL), Guidewire Software, Inc ... - KC Register - Today's Watch List: Curis, Inc. (NASDAQ:CRIS), Innocoll Holdings plc (NASDAQ:INNL), Guidewire Software, Inc ...KC RegisterBeta of Guidewire Software, Inc. (NYSE:GWRE) is 1.64 while company weekly performance is 3.68%. On 23 May, GTx, Inc. (NASDAQ:GTXI) hired David O'Connor and Jean Darsses as senior sales executives to support sales of spot and covered FX products.and more »
05/24/16 01:43 PMGTx, Inc. (NASDAQ:GTXI) Quarterly EPS From Continuing Operations Stands At $0.0149 - Investor Newswire - GTx, Inc. (NASDAQ:GTXI) Quarterly EPS From Continuing Operations Stands At $0.0149Investor NewswireGTx, Inc. (NASDAQ:GTXI) diluted EPS from parent firm came at $-0.1266 for the year ended 2016-03-31. For the quarter ended 2016-03-31 it came at $-0.1266. GTx, Inc. (NASDAQ:GTXI) posted net basic EPS of $-0.48 for the year ended 2016-03-31. For the ...
05/16/16 06:00 AMGTx Announces Webcast of Corporate Presentation at the UBS Global Healthcare Conference 2016 - [Business Wire] - GTx, Inc. announced today that management will present a company overview on May 24, 2016, at the UBS Global Healthcare Conference in New York City. The GTx presentation will begin at 11:30 am EST.
05/11/16 07:03 AMGTx Inc.: GTx Provides Corporate Update and Reports First Quarter 2016 Financial Results - MEMPHIS, Tenn.--(BUSINESS WIRE)--May 10, 2016-- GTx, Inc. (Nasdaq: GTXI) today reported financial results for the first quarter ended March 31, 2016, and highlighted recent accomplishments and upcoming milestones. The Company is currently enrolling ...
05/10/16 06:18 AMGTx Provides Corporate Update and Reports First Quarter 2016 Financial Results - [at noodls] - MEMPHIS, Tenn.--(BUSINESS WIRE)--May 10, 2016-- GTx, Inc. (Nasdaq: GTXI) today reported financial results for the first quarter ended March 31, 2016, and highlighted recent accomplishments and upcoming ...
05/10/16 06:14 AMGTx posts 1Q profit -
05/10/16 06:07 AMQ1 2016 GTX Inc Earnings Release - Before Market Open -
05/09/16 06:00 AMGTx Announces Presentation of Preclinical Data Demonstrating the Ability of SARDs to Degrade and Inhibit the Androgen Receptor at the American Urological Association Annual Meeting - [Business Wire] - GTx, Inc. today announced the first public presentation of preclinical data from the Company’s selective androgen receptor degrader program. The results demonstrate that the Company’s highly potent SARDs selectively bind to the ligand binding domain and interact with the N-terminal domain of the androgen receptor and inhibit and degrade the AR at very low concentrations.
05/06/16 10:06 PMNVIDIA CEO Jen-Hsun Huang Unveils GeForce GTX 1080, World’s Most Advanced GPU - [at noodls] - Whaaaatt? WHAT! Crazy! I WANT IT. HOLY %#%! And those are just the shouts we can report here. Hundreds of gamers gathered for a surprise event shrieked with delight and yelped encouragement as NVIDIA CEO ...
04/27/16 06:21 AMGTx, Inc. to Report First Quarter 2016 Financial Results on May 10, 2016 - [at noodls] - MEMPHIS, Tenn.--(BUSINESS WIRE)--Apr. 27, 2016-- GTx, Inc. (NASDAQ: GTXI) today announced that the timing for its first quarter 2016 financial results press release will be Tuesday, May 10, 2016, prior ...
04/20/16 08:56 AMGTx (GTXI) Worth a Look: Stock Moves 6.9% Higher - GTx, Inc. (GTXI - Snapshot Report) was a big mover last session, as the company saw its shares rise almost 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the ...
04/13/16 02:17 AMNikkei rallies to 1-1/2 week high on weaker yen, China trade data - TOKYO, April 13 (Reuters) - Japanese stocks surged to a fresh 1-1/2 week high on Wednesday as exporters gained on a retreat by the yen while appetites for riskier assets were lifted by upbeat Chinese...
04/07/16 11:59 AMNew Market Research Report: Cancer Cachexia Global Clinical Trials Review, H1, 2016 - Companies Mentioned in this Report: GTx, Inc., Helsinn Holding S.A., Medpace, Inc., Novartis AG, XBiotech USA, Inc., Ono Pharmaceutical Co., Ltd., Ohr Pharmaceutical Inc., Merck & Co., Inc., Ark Therapeutics Limited, Aeterna Zentaris Inc. About Fast Market ...
04/06/16 04:24 PMEdited Transcript of GTXI earnings conference call or presentation 3-Mar-16 2:00pm GMT -
04/06/16 01:35 PM2016 Duchenne Muscular Dystrophy Pipeline Market Covering 41 Companies - Inc., Galapagos NV, Genethon, GTx, Inc., Idera Pharmaceuticals, Inc., Italfarmaco S.p.A., La Jolla Pharmaceutical Company, Marathon Pharmaceuticals, LLC, Marina Biotech, Inc., Merck KGaA, Milo Biotechnology LLC, MyoTherix Inc., NicOx S.A., Nippon Shinyaku ...
03/31/16 01:45 PMA Daily Pill to Treat Postmenopausal Women with Stress Urinary Incontinence - "Beaumont urologists helped develop the protocol for this study with GTx Inc., a Memphis, Tennessee-based biopharmaceutical company, and is the only center offering this treatment," explained Dr. Peters.
03/31/16 01:45 PMBeaumont urologists study use of enobosarm to treat women's SUI - "Beaumont urologists helped develop the protocol for this study with GTx Inc., a Memphis, Tennessee-based biopharmaceutical company, and is the only center offering this treatment," explained Dr. Peters.
03/30/16 12:47 PMResearchers to look at pill to treat postmenopausal women with stress urinary incontinence - "Beaumont urologists helped develop the protocol for this study with GTx Inc., a Memphis, Tennessee-based biopharmaceutical company, and is the only center offering this treatment," explained Dr. Peters. Beaumont Health. (2016, March 29). Researchers to ...
03/30/16 09:13 AMGIGABYTE Announces GTX 960 XTREME GAMING - [at noodls] - GV-N960XTREME-4GD Taipei, Taiwan, March 29th, 2016 - GIGABYTE, the world's leading premium gaming hardware manufacturer, today announced the release of GTX 960 XTREME GAMING graphics card - GV-N960XTREME-4GD. ...
03/15/16 03:18 PMGTX INC /DE/ Files SEC form 10-K, Annual Report -
03/11/16 01:55 PMNew drug combination 'destroys' tumours in under two weeks - The EMERALD study, funded by Cancer Research UK, Clatterbridge Cancer Charity, Novartis and GTx Inc., will be the first study to investigate the effects of a drug called "enobosarm" (GTx) in early untreated, newly diagnosed breast cancer, which is both ...
03/03/16 01:33 PMGTX Inc Earnings Call (Q4 2015) - GTx, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecules that selectively modulate the effects of certain hormones produced by the body. The company is developing selective androgen receptor modulators ...
03/03/16 01:33 PMGTX : DE/ : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - ITEM 2.02 Results of Operations and Financial Condition. On March 3, 2016, GTx, Inc. issued its financial press release for the fourth quarter and year ended December 31, 2015, a copy of which is furnished as Exhibit 99.1 to this Current Report.
03/03/16 01:33 PMGTx Inc.: GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results - -- Patient enrollment underway in Phase 2 proof-of-concept clinical trial of enobosarm in women with Stress Urinary Incontinence; anticipate top-line data in 2016 -- -- Conference call today at 9:00 a.m. Eastern Time -- MEMPHIS, Tenn.--(BUSINESS WIRE)--Mar ...
03/03/16 08:00 AMGTX Inc Earnings Call scheduled for 9:00 am ET today -
03/03/16 06:31 AMGTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
03/03/16 06:17 AMGTx reports 4Q loss -
03/03/16 06:07 AMQ4 2015 GTX Inc Earnings Release - Before Market Open -
03/03/16 06:00 AMGTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2015 Financial Results - [Business Wire] - GTx, Inc. today reported financial results for the fourth quarter and year ended December 31, 2015, and highlighted recent accomplishments and upcoming milestones. The Company is currently enrolling patients in three clinical trials: two trials evaluating enobosarm as a potential treatment for women with advanced breast cancer, and another assessing enobosarm as a potential treatment for stress urinary ...
02/24/16 12:37 PMGTx reveals pre-clinical success for potential SUI treatment - GTx Inc (NASDAQ:GTXI) has told investors it has shown that its technology can increase pelvic floor muscle mass and ‘turn off’ genes associated with muscle degradation. A Phase 2 proof-of-concept clinical trial is currently being conducted for ...
02/24/16 06:06 AM7:06 am GTX announces preclinical data demonstrating that GTx-024 and GTx-027 reverse the observed loss of pelvic floor muscle in an animal model will be presented at the SUFU on February 24 -
02/24/16 06:00 AMGTx Announces Presentation of Preclinical Data Demonstrating the Effect of GTx SARMs on Pelvic Floor Muscle Loss at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Meeting - [Business Wire] - GTx, Inc. today announced preclinical data demonstrating that two of the Company’s selective androgen receptor modulators , GTx-024 and GTx-027, are able to increase pelvic floor muscle mass as well as turn off genes that are associated with muscle degradation in an ovariectomized mouse model.
02/18/16 06:00 AMGTx, Inc. to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast - [Business Wire] - GTx, Inc. today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's fourth quarter and full year 2015 financial results on Thursday, March 3, 2016 at 9:00 a.m.
01/29/16 10:04 AMWet macular degeneration pipeline comparative analysis review H2 2015 scrutinized in new research - Eleven Biotherapeutics Inc., Exonate Limited, F. Hoffmann-La Roche Ltd., Formycon AG, GTx, Inc., iCo Therapeutics Inc., Icon Bioscience, Inc., Kala Pharmaceuticals, Inc., Mabion SA, Mitotech S.A., Neurotech Pharmaceuticals, Inc., Novartis AG, Ocular ...
01/16/16 05:56 PMFiling Details - The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, GTx, Inc. or a shareholder of GTx, Inc. full information regarding the number of shares and prices at ...
11/09/15 03:59 PMGTX INC /DE/ Files SEC form 10-Q, Quarterly Report -
11/04/15 12:07 AMAffordable and Powerful Gaming with BIOSTAR's GeForce GTX 750 Ti VGA Card and Hi-Fi Z170Z5 Mainboard - Great value for gamers with special gaming OC revisionand FPS unique dualfan cooling design ... more - [at noodls] - November 3rd, 2015, Taipei, Taiwan -BIOSTAR's latest NVIDIA based GPU, the GeForce GTX 750 Ti is a VGA card that features the first-generation Maxwell GPU technology. Combined with an Intel based motherboard ...
11/02/15 02:55 PMEdited Transcript of GTXI earnings conference call or presentation 29-Oct-15 1:00pm GMT -
About GTx

GTx logoGTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). As of December 31, 2014, the Company's lead product candidate, Enobosarm (GTx-024), for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer and for the treatment of women with estrogen receptor (ER) positive and AR positive advanced breast cancer, was in Phase II clinical development stage. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with castration resistant prostate cancer (CRPC).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GTXI
  • CUSIP: 40052B10
Key Metrics:
  • Previous Close: $0.58
  • 50 Day Moving Average: $0.674
  • 200 Day Moving Average: $0.656
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $83.35M
  • Current Quarter EPS Consensus Estimate: $-0.110 EPS
Additional Links:
GTx (NASDAQ:GTXI) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha